Chairman
Siegfried Kasper (Austria)

Co-Chairman
Stuart A. Montgomery (United Kingdom)

Scientific Advisers (invited)
C. Allgulander (Sweden), C.A. Altamura (Italy), C. Arango (Spain),
D. Baldwin (United Kingdom), B. Bandelow (Germany), M. Bauer (Germany),
P. Boyer (Canada), G.B. Cassano (Italy), K. Demyttenaere (Belgium),
J. Den Boer (The Netherlands), T. Dinan (Ireland), E. Eriksson (Sweden),
N. Fineberg (United Kingdom), T. Higuchi (Japan), S.H. Kennedy (Canada),
D. Lecic Tosevski (Serbia), J.P. Lépine (France), M. Maj (Italy), A.A. Mathé (Sweden),
J. Mendlewicz (Belgium), H.J. Möller (Germany), S. Pallanti (Italy),
G. Papadimitriou (Greece), G. Papakostas (USA), Z. Rihmer (Hungary),
T. Roth (USA), A. F. Schatzberg (USA), I. Schweitzer† (Australia), A. Serretti (Italy),
D.J. Stein (South Africa), T. Svensson (Sweden), T. Suppes (USA), E. Vieta (Spain),
D. Winkler (Austria), S. Yamawaki (Japan), A. Young (UK), J. Zohar (Israel)

ORGANIZING SECRETARIAT

PUBLI CREATIONS
74, Bd d’Italie - 98000 Monte-Carlo - Monaco
Ph. +377 97973555 - Fax +377 97973550
E-mail: ifmad@publiccreations.com
Website: www.ifmad.org

Forum Venue
FAIRMONT MONTE CARLO
12, Av. des Spéluges
98000 Monaco
Tel. + 377 93506500
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Committee</td>
<td>2</td>
</tr>
<tr>
<td>Organizing Secretariat</td>
<td>2</td>
</tr>
<tr>
<td>Forum Venue</td>
<td>2</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td>Welcome Letter</td>
<td>5</td>
</tr>
<tr>
<td>Programme Overview</td>
<td>6</td>
</tr>
<tr>
<td>Advance Scientific Programme</td>
<td>7</td>
</tr>
<tr>
<td>Registration and Payment</td>
<td>13</td>
</tr>
<tr>
<td>Hotel Accommodation and Payment</td>
<td>14</td>
</tr>
<tr>
<td>General Information</td>
<td>15</td>
</tr>
<tr>
<td>Cut out Forms:</td>
<td>17</td>
</tr>
<tr>
<td><em>Registration Form</em></td>
<td></td>
</tr>
<tr>
<td><em>Hotel Accommodation Form</em></td>
<td></td>
</tr>
</tbody>
</table>

Forms available on internet: www.ifmad.org
The Organizing Committee expresses their gratitude for their contribution of unrestricted educational grants

LUNDBECK
for their unrestricted grant as Sponsor of Symposia

PIERRE FABRE MEDICAMENT
for their contribution as sponsor of the speaker’s dinner
To all prospective delegates,

The International Forum on Mood and Anxiety Disorders (IFMAD) will be held from 20 to 22 November 2013 in Monte-Carlo, Monaco.

The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegiate atmosphere, and digested over dinner.

The meetings are always enjoyable and informative and along with the usual updates on new treatments this year’s IFMAD will be an efficient way of catching up with the latest developments.

This year topics that will be addressed include the following: lithium medicine or myth, the hurtful brain, cognition as a treatment target in mood disorders, depression and cognitive and negative symptoms in schizophrenia, treatment resistant depression, treatment of MDD.

We invite you to join us again in November 2013 to give you the opportunity to keep abreast of the latest advances.

It will be our pleasure to welcome you in Monte-Carlo.

Siegfried Kasper, Chairman

Stuart A. Montgomery, Co-Chairman
<table>
<thead>
<tr>
<th>Time</th>
<th>Session ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00/10.30</td>
<td>SO 03</td>
<td>Recovery - the new treatment goal in depression? - A debate</td>
</tr>
<tr>
<td>10.30/11.00</td>
<td></td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.00/12.30</td>
<td>SO 04</td>
<td>Cognition as a treatment target in mood disorders</td>
</tr>
<tr>
<td>12.30/13.30</td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>13.30/15.00</td>
<td>SO 05</td>
<td>Cognitive dysfunction in major depressive disorder - patient perceptions and objective measures</td>
</tr>
<tr>
<td>15.00/16.30</td>
<td>SO 06</td>
<td>Depression, cognitive and negative symptoms in schizophrenia: Underlying neurobiology and novel leads for pharmacological treatment</td>
</tr>
<tr>
<td>16.30/16.45</td>
<td></td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.45/18.15</td>
<td>SO 07</td>
<td>Adherence with treatment</td>
</tr>
<tr>
<td>18.15/19.15</td>
<td></td>
<td>Meet the Expert</td>
</tr>
</tbody>
</table>

NB: This agenda is subject to change
14.30-16.00  SO 01 LITHIUM MEDICINE OR MYTH
Chair:  T. DINAN (Ireland)
        S. MONTGOMERY (UK)

14.30-15.00  SO 0101 Lithium in acute treatment of bipolar disorder
            Rasmus LICHT (Denmark)
15.00-15.30  SO 0102 Bipolar maintenance treatment
            Heinz GRUNZE (United Kingdom)
15.30-16.00  SO 0103 Lithium: Still the gold standard for augmenting antidepressants?
            Timothy DINAN (Ireland)

➤ Please note that a 5’ discussion with the speaker is foreseen at the end of each presentation.

16.00-16.30  Coffee break

16.30-18.00  SO 02 THE HURTFUL BRAIN
Chair:  J. DEN BOER (The Netherlands)
        R. LICHT (Denmark)

16.30-17.00  SO 0201 The comorbidity of pain, anxiety and depression
            Hans-Ulrich WITTCHEN (Germany)
17.00-17.30  SO 0202 Explaining the co-occurrence of pain, anxiety and depression
            Johan DEN BOER (The Netherlands)
17.30-18.00  SO 0203 Psychotropics as treatments for pain
            Michael BACH (Germany)

➤ Please note that a 5’ discussion with the speaker is foreseen at the end of each presentation.

18.00-19.00  Opening Ceremony
THURSDAY, 21 November 2013

09.00-10.30 SO 03 RECOVERY – THE NEW TREATMENT GOAL IN DEPRESSION? – A DEBATE
Moderator: A. WADE (UK)

09.00-09.10 Welcome and introduction

09.10-09.30 SO 0301 Is recovery a better treatment goal than remission?
Koen DEMYTTENAERE (Belgium),
Thomas E. SCHLÄPFER (Germany)

09.35-09.55 SO 0302 What assessment tools should be used for evaluating whether the treatment goal has been achieved?
Koen DEMYTTENAERE (Belgium),
Thomas E. SCHLÄPFER (Germany)

10.00-10.20 SO 0303 What would be the best approach to changing treatment for patients not achieving the treatment goal upon antidepressant therapy?
Koen DEMYTTENAERE (Belgium),
Thomas E. SCHLÄPFER (Germany)

10.25-10.30 Discussion and closing remarks
All sessions will be followed by a 5’ session of Questions and Answers chaired by Alan WADE (UK)

10.30-11.00 Coffee break

11.00-12.30 SO 04 COGNITION AS A TREATMENT TARGET IN MOOD DISORDERS
Chair: H.J. MÖLLER (Germany)  
D. BALDWIN (UK)

11.00-11.30 SO 0401 The treatment of cognitive impairment in OCD
Naomi FINEBERG (UK)

11.30-12.00 SO 0402 The treatment of cognitive deficits in MDD
David BALDWIN (UK)

12.00-12.30 SO 0403 Cognitive deficits in bipolar disorder
Eduard VIETA (Spain)

➤ Please note that a 5’ discussion with the speaker is foreseen at the end of each presentation.
12.30-13.30  Lunch

13.30-15.00  SO 05 COGNITIVE DYSFUNCTION IN MAJOR DEPRESSIVE DISORDER - PATIENT PERCEPTIONS AND OBJECTIVE MEASURES
Chair: M. DORAISWAMY (USA)

13.30-13.35  Welcome and introduction

13.35-14.00  SO 0501 Do patients and physicians have the same perceptions of cognitive symptoms in depression?
Lawrence MARTIN (Canada)

14.00-14.25  SO 0502 Cognitive dysfunction in depressed patients: prevalence, risks and consequences
Barbara SAHAKIAN (UK)

14.25-14.50  SO 0503 Assessment of cognitive dysfunction in depression
Murali DORAISWAMY (USA)

14.50-15.00  Discussion and closing remarks

15.00-16.30  SO 06 DEPRESSION, COGNITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: UNDERLYING NEUROBIOLOGY AND NOVEL LEADS FOR PHARMACOLOGICAL TREATMENT
Chair: S. KASPER (Austria)
J. LOFTUS (Monaco)

15.00-15.30  SO 0601 Do depressive cognitive and negative symptoms impact on outcome in schizophrenia?
Hans-Juergen MOELLER (Germany)

15.30-16.00  SO 0602 Neurobiological mechanisms and novel targets for cognitive improvement
Torgny SVENSSON (Sweden)

16.00-16.30  SO 0603 Antidepressant drugs in schizophrenia and antipsychotic drugs in depression: basic and clinical perspective
Siegfried KASPER (UK)

➤ Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.
16.30-16.45  Coffee break

16.45-18.15  SO 07 ADHERENCE WITH TREATMENT
Chair: C. ALTAMURA (Italy)  
H.P. VOLZ (Germany)

16.45-17.15  SO 0701  Compliance counselling in bipolar disorder  
Carla TORRENT (Spain)

17.15-17.45  SO 0702  The treatment of cognitive deficits in MDD  
Hans-Peter VOLZ (Germany)

17.45-18.15  SO 0703  Are any drug formulations inherently better  
for both adherence and effectiveness?  
Carlo ALTAMURA (Italy)

➤ Please note that a 5’ discussion with the speaker is foreseen at the end of each presentation.

18.15-19.15  MEET THE EXPERT SESSION  
Siegfried KASPER (Austria)  
Stuart MONTGOMERY (UK)
Limited number of seats
FRIDAY, 22 November 2013

09.00-10.30  SO 08 - THE REVISED DIAGNOSTIC CRITERIA OF MENTAL DISORDERS (DSM-5): BIPOLAR DISORDER IS BIPOLAR AGAIN – REVISITING THE CLASSICS

Chair: M. DAVIDSON (Israel)

09.00-09.10  Welcome and introduction
SO 0801 DSM-5 – a critical appraisal
Michael DAVIDSON (Israel)

09.10-09.30  SO 0802 DSM-5 criteria for bipolar disorder: what has changed?
Alan SWANN (USA)

09.30-10.00  SO 0803 Implications for clinical management: State of the art treatment of mixed Mania - New data
Eduard VIETA (Spain)

10.00-10.30  Panel discussion Closing remarks

10.30-11.00  Coffee break

11.00-12.30  SO 09 - TREATMENT RESISTANT DEPRESSION

Chair: S. MONTGOMERY (UK)
S. KASPER (Austria)

11.00-11.30  SO 0901 Is resistant depression a signal for bipolar disorder?
Alessandro SERRETTI (Italy)

11.30-12.00  SO 0902 My preferred treatments in TRD
Stuart A. MONTGOMERY (UK)

12.00-12.30  SO 0903 New finding in resistant depression - focus on anxiety comorbidity
Joseph ZOHAR (Israel)

➤ Please note that a 5’ discussion with the speaker is foreseen at the end of each presentation.
12.30-13.30  **Lunch**

13.30-15.00  **SO 10 - TREATMENT OF MDD**
   Chair:  *E. ERIKSSON (Sweden)*  
   *A. SERRETTI (Italy)*

   13.30-14.00  SO 1001  The effect of comorbid anxiety on outcomes in MDD
   *Borwin BANDELOW (Germany)*

   14.00-14.30  SO 1002  Does being elderly alter response in MDD?
   *Cornelius KATONA (UK)*

   14.30-15.00  SO 1003  Double standards when evaluating the evidence base for CBT and pharmacological treatment, respectively: a critical analysis of guidelines from NICE and other bodies
   *Elias ERIKSSON (Sweden)*

15.00-16.30  **SO 11 - HOT TOPICS**
   Chair:  *B. BANDELOW (Germany)*  
   *C. KATONA (UK)*

   15.00-15.30  SO 1101  Behavioural Addictions in adult ADHD
   *Pierre-Michel LLORCA (France)*

   15.30-16.00  SO 1102  Biomarkers and prediction of response in MDD – an update.
   *Dietmar WINKLER (Austria)*

   16.00-16.30  SO 1103  Neuropeptide Y and CRH in MDD
   *Aleksander A. MATHÉ (Sweden)*

16.30-16.45  **End of meeting**
Registration
Registrations can be made directly through our website www.ifmad.org, (on-line payment by credit card is in a secure certificate mode) or by filling up the Registration Form enclosed in this programme.

An invoice, that will serve as a confirmation letter of registration, will be sent to all delegates upon receipt of their payment.

Please note that registration will only be confirmed once payment has been received. Please send the Registration Form together with the payment to the following fax number: +377 97 97 35 50, by post to: PUBLI CRÉATIONS 74, Boulevard d’Italie - MC 98000 Monte-Carlo (Monaco) or by e-mail: ifmad@publiccreations.com

Registration Fees (+ V.A.T. 19,6%)

<table>
<thead>
<tr>
<th>FEE</th>
<th>Early</th>
<th>Late</th>
<th>On site</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 September 2013</td>
<td>30 September 2013 until 04 November 2013</td>
<td>After 04 November 2013 and on site</td>
</tr>
<tr>
<td>AREA 1 (Canada, North America, Europe Region, South Pacific)</td>
<td>€ 410</td>
<td>€ 460</td>
<td>€ 580</td>
</tr>
<tr>
<td>AREA 2 (Mexico, Central America, Caribbean Region, South America, Middle East)</td>
<td>€ 330</td>
<td>€ 375</td>
<td>€ 480</td>
</tr>
<tr>
<td>AREA 3 (Africa, Asia)</td>
<td>€ 285</td>
<td>€ 350</td>
<td>€ 450</td>
</tr>
<tr>
<td>TRAINEES* and STUDENTS*</td>
<td>€ 180</td>
<td>€ 235</td>
<td>€ 300</td>
</tr>
<tr>
<td>ACCOMPANYING PERSON</td>
<td>€ 130</td>
<td>€ 130</td>
<td>€ 130</td>
</tr>
<tr>
<td>Meet the Expert</td>
<td>€ 30</td>
<td>€ 30</td>
<td>€ 30</td>
</tr>
</tbody>
</table>

*Please, provide certification

Registration fee includes:
- Attendance to all Scientific Sessions • Opening Ceremony • Welcome Reception
- Lunches and Refreshments during breaks • Congress kit • Entrance to the Exhibition

Accompanying fee includes:
- Welcome Reception • Lunches and Refreshments during breaks

Cancellations and Refunds:
Cancellation or modification of registration must be sent in writing to the Organizing Secretariat Publi Créations (ifmad@publiccreations.com).
Before 30 September all fees will be refunded minus 20%. All amounts will be settled after the Forum.
After 30 September no refunds will be made.
After 30 September all name changes will be invoiced € 36.
The above rates are in Euro, are intended per night and include buffet breakfast, VAT and service charges.
Others hotels are available upon request at: ifmad@publiccreations.com
Deadline for hotel reservation is: 30 September, 2013. Requests after this date are subject to availability.

Hotel Reservations
Reservation can be made directly through our website www.ifmag.org or using the Hotel Accommodation Form enclosed in this programme which must be accompanied by the relevant payment (amount of the entire length of stay). Rooms will be allocated on a first come, first served basis. Confirmation of your accommodation booking (invoice) will be sent to you upon receipt of the payment.

Cancellations and Refunds:
In case of cancellations after 30 September 2013 you will be charged 100% of the room rate for the entire length of stay. In case of no-show, the amount paid is not refundable and the reservation will be automatically cancelled.

Methods of payment
Payments of registration and accommodation, must be made in Euro by one of the following methods:

• By Bank Transfer: please transfer the payment to PUBLI CRÉATIONS S.A.M.
  Bank details: Bank Julius BAER (Monaco)
  1, avenue des Citronniers - MC 98000 Monaco (MC)
  IBAN: MC 23 1450 8000 0151 0479 3001 D18 - Bic (swift) BAERMCMC
  The payment transfer should be net of all charges to our Company and it should clearly state the “13th International Forum on Mood and Anxiety Disorders”.

• By Credit Card: only VISA and EUROCARD/MASTERCARD are accepted. Please enter the credit card number and the expiration date in the appropriate space on the Forms. Please note that the payment should be net of all charges to our company.

• By Internet: www.ifmag.org. Payment by credit card is in a secure certificate mode.

Inquiries: any inquiries or request for additional information, changes or cancellation of room reservations must be addressed directly to: Publi Créations - 74, Bd d’Italie 98000 Monte-Carlo - Monaco - Ph. +377 97973555 - Fax +377 97973550
ifmad@publiccreations.com - Website: www.ifmad.org
The «13th International Forum on Mood and Anxiety Disorder» will be held at the Fairmont Hotel from 20-22 November 2013.

**Admission**
The participant’s name badge will be provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders will be admitted to the appropriate sessions, exhibition and social events.

**Climate**
Monte-Carlo’s climate is usually mild. In November the average temperature is 12° C during the day.

**Congress venue**
FAIRMONT MONTE CARLO - 12, avenue des Spélugues
Tel : +377 93 50 65 00 - Fax : +377 93 30 01 57
www.fairmont.com

The Fairmont Monte Carlo Hotel sets sail for modern luxury and the pleasure of an inland cruise offering an experience of a life time. Right by the sea, the Fairmont Monte Carlo enhances its splendid entrance hall with an immense picture window, which allows guests to cast their eyes directly into the Mediterranean Sea.

The Fairmont Monte Carlo Hotel is perfectly situated only a few minutes walk away from the town center shops and services.

**Electricity**
The standard voltage in Monaco is 220 V.

**Language**
The official language of the Congress is English. No simultaneous translation will be provided.

**Insurance**
The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.

**Letter of invitation**
The Forum Secretariat will be please to send letters of invitation to any individual making such request. A letter of invitation often facilitates the procedure of obtaining a Visa. Please note that the letter is not a commitment on the part of the Forum to provide any financial support.

**Secretariat**
The secretariat desk will open on Wednesday, 20 November and stay open all through the Congress.
Transfer from / to the airport

The Nice Côte d’Azur International Airport is a major gateway to Southern Europe and only 22 kilometres from Monaco.

Comfortable and rapid travel is provided by numerous direct flights. Further information and a list of all the airlines flying to Nice can be found at www.nice.aeroport.fr.

How to get to Monaco

• By taxi
Prices for taxi transfers from Nice Airport to Monaco or from Monaco to Nice Airport are as follows:
- Day fares from € 90 to € 120 (one way)
- Night fares from € 95 to € 130 (one way)
Taxis are available outside the airport or can be ordered 24 hours a day on the following telephone numbers:
  in Nice +33 4 93 13 78 78   in Monaco 0820 20 98 98

• By Airport Shuttle Express
The Shuttle Express bus No. 110 runs from Nice Airport, Terminal 1 and 2, every hour, from 09.00 to 21.00. The bus will take the participant directly to the Hotel Fairmont.
  Departure Monaco: please check the schedule at the bus stop right outside the hotel or at www.uk.niceairportxpress.com

• By Helicopter
Heli Air Monaco offers numerous daily connections (every 30 minutes) from Nice Airport to Monaco – only 7 minutes away by helicopter. Upon arrival in Monaco, a complimentary shuttle service will take you to your hotel. Please check with Heli Air for your pick-up time and for departure at fabien@heliairmonaco.com   phone +377 92 05 00 33   fax +377 92 05 00 51   www.heliairmonaco.com

• Travelling by train
Rapid and SNCF express trains connect Monaco with all regions in France and all major European cities.
  Further information at French website: www.voyages-sncf.com
  English website: www.tgv-europe.com

Welcome cocktail

All delegates are cordially invited to attend the Welcome Cocktail of the Forum, which will be held on Wednesday, 20 November at 18.00 in the Galerie Crystal of the Fairmont.
Please use CAPITAL LETTERS (send back to +377 97 97 35 50 or ifmad@publiccreations.com)

Surname __________________________ Name __________________________

Private Address ________________________________________________

Zip code ___________ City __________________________ Country _______

Phone __________________________ Fax __________________________

E-mail __________________________________________________________

Institute Address ________________________________________________

Zip code ___________ City __________________________ Country _______

Phone __________________________ Fax __________________________

E-mail __________________________________________________________

For citizens of EEC countries Fiscal Code / V.A.T. number ____________

Registration fee (+ V.A.T. 19,6%)

<table>
<thead>
<tr>
<th>FEE</th>
<th>Before</th>
<th>After</th>
<th>Late</th>
</tr>
</thead>
</table>
| AREA 1  
(Canada, North America, Europe Region, South Pacific) | € 410 | € 460 | € 580 |
| AREA 2  
(Mexico, Central America, Caribbean Region, South America, Middle East) | € 330 | € 375 | € 480 |
| AREA 3  
(Africa, Asia) | € 285 | € 350 | € 450 |
| TRAINEES* | € 180 | € 235 | € 300 |
| Meet the Expert | € 30 | € 30 | € 30 |

*Please, provide certification

Accompanying person ☐ € 130

I wish to pay by:

☐ Credit Card:  ☐ Visa  ☐ Mastercard/Eurocard

Payment shall be made payable to PUBLI CRÉATIONS - Monte-Carlo

Card holder (Surname & First Name) __________________________

Card Number ________________________________________________

Expiry Date __________________________ Key code __________________________

☐ Bank Transfer made out to PUBLI CRÉATIONS (please enclose photocopy of bank receipt)

Bank details: JULIUS BAER (Monaco), 1, avenue des Citronniers, 98000 Monaco (MC)

IBAN MC 23 1450 8000 0151 0479 3001 D18 BIC (swift) BAERMCMC

Clearly State: “13th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS”

☐ Congress registration ☐ Meet the Expert

€ ______________

+ € ______________ V.A.T. 19,6% 

+ € 15 (Handling fees)

TOTAL € ______________

Date: ______________

Signature ______________

AUTHORISATION OF PERSONAL DATA - PUBLI CRÉATIONS SAM, as data controller and/or processor, informs you that any personal data you provide, or any data received by third parties, will be used in connection to your participation to the Congress and/or to provide you with information regarding any other compatible activities organized by PUBLI CRÉATIONS SAM or by its partners. Data treatment shall mean any operation, or set of operations, carried out with or without the help of electronic or automated means, and must guarantee the confidentiality and security of your personal data. The PUBLI CRÉATIONS SAM as data controller and/or processor may avail itself of its associates to carry out any of the following procedures: press releases, communications to clients, data processing and computer-based consultation. The data can be communicated to scientific associations, relative public or private agencies related to CME, financial and banking intermediaries, as well as companies participating in the Congress with promotional functions compatible with the purposes for which the data has been collected. The provision of your personal data is voluntary, but refusal will prevent your participation in the Congress. According to the law dated December 23, 1993, you shall have a right of access and correction of your personal data. Any requests can be addressed to PUBLI CRÉATIONS SAM - 74, Bd. d’Italie - 98000 Monte-Carlo, MC Monaco - Fax: +377 97 97 35 50.

I authorize the treatment and communication of my personal data as described above.
Please use CAPITAL LETTERS (send back to + 377 97 97 35 50 or ifmad@publiccreations.com)

Surname __________________________ Name __________________________
Address __________________________ City __________________________ Country __________________________
Phone __________________________ Fax __________________________
E-mail __________________________
Date of arrival __________________________ Date of departure __________________________
Type of room __________________________ Num. of Person(s) __________________________
Special request __________________________

Hotel FAIRMONT ****
(city and garden view category)

Double room single use € 185
Double room € 195

The above mentioned rates are per room per night including tax. Continental breakfast included.
Deadline for hotel reservation: 30 September 2013, requests after this date will be handled upon availability.

Deposit (equal to the price of the entire length of stay) Total €

I wish to pay by:

Credit Card: □ Visa □ Mastercard/Eurocard
Payment shall be made payable to PUBLI CRÉATIONS - Monte-Carlo
Card holder (Surname & First Name) __________________________
Card Number __________________________
Expiry Date __________________________ Key code __________________________

Bank Transfer made out to PUBLI CRÉATIONS (please enclose photocopy of bank receipt)

Bank details: JULIUS BAER (Monaco), 1, avenue des Citronniers, 98000 Monaco (MC)
IBAN MC 23 1450 8000 0151 0479 3001 D18 BIC (swift) BAERMCMC
Clearly State: “13th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS”

Hotel reservation € ________________
+ € 10 (Handling fees)
TOTAL € ________________

Date: __________________________ Signature __________________________
14th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

VIENNA, 05-07 NOVEMBER, 2014

www.ifmad.org

CHAIRMAN: Siegfried KASPER (Austria)

CO-CHAIRMAN: Stuart A. MONTGOMERY (United Kingdom)
Cipralex® - the power to tackle depression

References:

CIPRALEX (escitalopram) - Abbreviated Prescribing Information

Presentation Film-coated tablets 5 10 15 20 mg, oral drops, solution 10 20 mg/ml and orodispersible tablets 10 20 mg. Indication Treatment of major depressive episodes, Treatment of panic disorder with or without agoraphobia, Treatment of social anxiety disorder (social phobia), Treatment of generalised anxiety disorder, Treatment of obsessive compulsive disorder. Dosage Adults: The recommended starting dose is 10 mg once daily. Depending on individual patient response the dose may be increased to a maximum of 20 mg once daily. An initial starting dose of 5 mg once daily is recommended in the treatment of elderly (>65 years), in panic disorder and in patients with reduced hepatic function. Children and adolescents (<18 years). Cipralex should not be used. Discontinuation. Discontinue gradually over a period of at least one to two weeks to reduce the possibility of discontinuation symptoms. Contraindications Hypersensitivity to escitalopram or to any of the excipients. Patients with known QT interval prolongation or congenital long QT syndrome. In combination with MAO-inhibitors or with medicinal products known to prolong the QT interval. Should not be used during pregnancy unless clearly needed and after careful consideration of the risk/benefit. Breast-feeding is not recommended. Precautions Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide. It is a general clinical experience that the risk of suicide may increase in the early stages of recovery. Close supervision of high-risk patients should accompany drug therapy. Patients (and caregivers) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored. SSRIs should be used with caution in patients with a history of mania/hypomania. Treatment with SSRIs may alter glycemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted. The use of SSRIs/SNRIs has been associated with the development of akathisia. Hypotension has been reported rarely with the use of SSRIs. There have been reports of cutaneous bleeding abnormalities. There have been reports of QT interval prolongation and ventricular arrhythmia including torsades de pointes, predominantly in patients of female gender, with hypokalemia, or with pre-existing QT interval prolongation or other cardiac diseases. Interactions Caution is advised when taken in combination with MAO-inhibitors or medicinal products known to prolong the QT interval, serotonergic medicinal products, products lowering the seizure threshold, lithium, tricyclics, St. John’s Wort, oral anticoagulants or antiplatelet agents (NSAIDs), and products predominantly metabolised by the enzymes CYP2C19 and CYP2D6. Undesirable effects Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment. Very common: nausea. Common: decreased/increased appetite, weight increased, anxiety, restless ness, abnormal dreams, libido decreased, anorgasmia, insomnia, somnolence, dizziness, paraesthesia, tremor, sinusitis, yawning, diarrhoea, constipation, vomiting, dry mouth, sweating increased, arthralgia, myalgia, ejaculation disorder, impotence, fatigue and pyrexia. Uncommon: weight decreased, bruxism, agitation, nervousness, panic attack, confusional state, taste disturbance, sleep disorder, syncope, mydriasis, visual disturbance, tinnitus, tachycardia, epistaxis, gastrointestinal haemorrhage (including rectal haemorrhage), urticaria, alopecia, rash, pruritus, metrorrhagia, menorrhagia, oedema. Rare: anaphylactic reaction, aggression, depersonalisation, hallucination, serotonin syndrome, bradycardia. Not known: thrombocyto penia, inappropriate ADH secretion, hypoglycaemia, anorexia, mania, suicidal ideation, suicidal behaviour, dyskinesia, movement disorder, convulsion, psychomotor restlessness/akathisia, electrocardiogram QT prolonged, ventricular arrhythmia including torsades de pointes, orthostatic hypotension, hepatitis, liver function test abnormal, ecchymosis, angioedema, urinary retention, galactorrhoea, priapism. Class effects: Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs. Overdose Cases of overdose with escitalopram doses between 400 mg and 800 mg have been reported without any severe symptoms. Legal category POM. Date of preparation or last review August 2013 Full Prescribing Information is available from H. Lundbeck A/S, Ottiliavej 5, 2900 Valby, Denmark.